Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 600 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

HOV156

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy (NCT04027309)

Currently recruiting

HP518-CS-001 HINOVA

A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral HP518 in Patients with Metastatic Castration-Resistant Prostate Cancer HP518-CS-001 (NCT05252364)

Recently completed/closed

I-MAT

A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma (NCT04291885)

Currently recruiting

IBIS

An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS study (ACTRN12621001037897)

Currently recruiting

ICE EXAPANCE

The Intelligent Computerized Engine (ICE) Aspiration System Clinical Study: First In Human

Recently completed/closed

IDE196-002

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (NCT05987332)

Currently recruiting

IDE196-009

(NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA (NCT05907954)

Currently recruiting

IIHRepurposing1

A phase 2 randomised, placebo- controlled, double-blind pilot trial of drug repurposing in idiopathic intracranial hypertension (ACTRN12625000401459)

Currently recruiting

IKS014-01 IKSUDA

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors (NCT05872295)

Currently recruiting

IMC-F106C-101

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers (NCT04262466)

Currently recruiting

IMC-I109V-101

An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Patients with Chronic HBV who are Non-Cirrhotic, Hepatitis B e Antigen-negative, and Virally Suppressed (ACTRN12620000403932)

Currently recruiting

IMPAHCT

IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in patients with Pulmonary Arterial Hypertension (PAH). (NCT05036135)

Currently recruiting

INCA 33989-101

A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT05936359)

Currently recruiting

INCB 161734-101

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160)

Currently recruiting

INCMOR 0208-301

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma (INCMOR0208-301) (NCT04680052)

Currently recruiting

INCYTE INCB 18424-320

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis (NCT05764161)

Recently completed/closed

INDEPENDENCE

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (The INDEPENDENCE trial) (NCT04717414)

Currently recruiting

INDEX-AF

The role of pharmacological heart failure therapy in LV recovery following INDEX catheter ablation for atrial fibrillation [AF] induced cardiomyopathy - the INDEX-AF Study (Registration Pending)

Coming soon

INFINITE

A Phase III Randomised Crossover Trial to Assess Feasibility of Domiciliary Nasal High Flow for Chronic Breathlessness in People with Interstitial Lung Disease (ACTRN12623000835640p)

Currently recruiting

InflaRx IFX-1-P3.4

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ADAPTIVE PHASE III TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF VILOBELIMAB IN THE TREATMENT OF ULCERATIVE PYODERMA GANGRENOSUM (NCT05964413)

No longer recruiting
14 15 16 17 18